Consistent with the outcomes of DHE fluorescent staining, AO fluorescent staining revealed a higher prevalence of apoptosis in the CML injected group that was significantly 2.4-fold (p < 0.05) and 5.2-fold (p < 0.01) reduced following the treatment of apoA-I:GIGB-258 at the molar ration of 1:0.5 and 1:1; testifying the anti-apoptotic role of apoA-I in combination with GIGB-258. This evidence concerns the gene APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive.